Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Using Discrete Choice Experiment to Determine Willingness to Pay for Interferon-Beta Drugs by Multiple Sclerosis Patients Publisher



Rahimi F1 ; Rasekh HR2 ; Abbasian E3 ; Peiravian F2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Health Management and Economics Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Pharmacoeconomics and Pharmaceutical Management, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Economics, Bu Ali Sina University, Hamedan, Iran

Source: Iranian Journal of Pharmaceutical Sciences Published:2018


Abstract

This study explores the effects of Interferon-β characteristics such as country of origin, injection frequency and method, monthly cost, effectiveness, and side effects on multiple-sclerosis patients’ willingness to pay. For this purpose, MS patients with a history of using Interferon-β were studied from the three major Isfahan MS centers. Choice sets were designed with a combination of attributes and levels. The variables in this experiment included interferon-β with different levels assigned to each of its attribute. Patient preferences and willingness to pay were calculated through Discreet Choice Experiment. The statistical population consisted of 358 patients deemed eligible for the study. They responded to the questionnaire and took part in interviews. Results showed that the highest willingness-to-pay value of US$ 223 as determined by MS patients belonged to a change of effectiveness from moderate to high. Side-effects and ease of use ranked next among patient preferences. Country of origin recorded the lowest value of the willingness-to-pay parameter. Evaluation of MS patients' preferences as reflected in their willingness to pay plays an important role in patient’s adherence to treatment to achieve more effective results. Due to the variety of drugs in this category, it is necessary to identify and prioritize those features that are of interest to patients and that increase their utility relative to IFN-β drugs. © 2018, Iranian Association of Pharmaceutical Scientists. All rights reserved.
Related Docs
View other Related Docs
1. Patient Preferences for Interferon-Beta in Iran: A Discrete Choice Experiment, PLoS ONE (2018)
2. A New Approach to Pharmaceutical Pricing Based on Patients’ Willingness to Pay, Tropical Medicine and International Health (2018)
3. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
4. A Report of Multiple Sclerosis Patients Treated by Cinnovex™ in Iran, Tehran University Medical Journal (2010)
5. Covid-19 Vaccines and Patients With Multiple Sclerosis: Willingness, Unwillingness and Hesitancy: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
6. Antibodies to Interferon Beta in Patients With Multiple Sclerosis Receiving Cinnovex, Rebif, and Betaferon, Journal of Korean Medical Science (2013)
7. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018, CNS Drugs (2021)
8. Predictors of Treatment Switching in the Big Multiple Sclerosis Data Network, Frontiers in Neurology (2023)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (19)
Masoud Etemadifar (16)
Other Related Docs
9. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
10. Covid-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran, Vaccines (2022)
11. Investigating the Occurrence of Femoral Head Avascular Necrosis in Patient With Multiple Sclerosis Treated With Interferon-Beta, Journal of Isfahan Medical School (2018)
12. Comparison of Interferon Beta Products and Azathioprine in the Treatment of Relapsing-Remitting Multiple Sclerosis, Journal of Neurology (2007)
13. The Effectiveness of Natalizumab Vs Fingolimod–A Comparison of International Registry Studies, Multiple Sclerosis and Related Disorders (2021)
14. Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis, JAMA - Journal of the American Medical Association (2019)
15. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
16. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
17. Effectiveness of Multiple Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis: Causal Inference to Emulate a Multiarm Randomised Trial, Journal of Neurology, Neurosurgery and Psychiatry (2023)
18. Expectations of Multiple Sclerosis Patients and Their Families: A Qualitative Study in Iran, Iranian Red Crescent Medical Journal (2015)
19. Neutralizing Antibodies in Multiple Sclerosis Patients on Weekly Intramuscular Avonex and Biosimilar Interferon Beta-1A (Cinnovex): Comparing Results of Measurements in Two Different Laboratories, Journal of Immunological Methods (2013)
20. Comparing Side Effects of Cinnovex With Avonex in Relapsing Remitting Multiple Sclerosis Patients, Journal of Isfahan Medical School (2009)
21. Economic and Social Standing of Individuals in Iran Diagnosed With Multiple Sclerosis, Archives of Iranian Medicine (2023)
22. Prevalence of Multiple Sclerosis in Isfahan, Iran, Neuroepidemiology (2006)
23. Public and Decision-Maker Stated Preferences for Pharmaceutical Subsidy Decisions in Iran: An Application of the Discrete Choice Experiment, Journal of Pharmaceutical Policy and Practice (2021)
24. Ongoing Increase in Incidence and Prevalence of Multiple Sclerosis in South-Eastern Iran: A Three Decade Study, Multiple Sclerosis and Related Disorders (2023)
25. Alternate Dosing of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2023)
26. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
27. Comparative Effectiveness and Cost-Effectiveness of Natalizumab and Fingolimod in Rapidly Evolving Severe Relapsing-Remitting Multiple Sclerosis in the United Kingdom, Journal of Medical Economics (2024)
28. Potential of Modified Mediterranean Diet to Improve Quality of Life and Fatigue Severity in Multiple Sclerosis Patients: A Single-Center Randomized Controlled Trial, International Journal of Food Properties (2020)
29. Interdependency of Ninj2 Gene Expression and Polymorphism With Susceptibility and Response to Interferon Beta in Patients With Multiple Sclerosis, International Journal of Neuroscience (2024)
30. Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase Iv, Post-Marketing, Prospective, Multicenter Study, Archives of Iranian Medicine (2023)
31. Comparison Effect of Prescription Drugs on the Occurrence and the Number of Attacks in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2018)
32. Comparison of Fingolimod, Dimethyl Fumarate and Teriflunomide for Multiple Sclerosis, Journal of Neurology, Neurosurgery and Psychiatry (2019)
33. Comparable Efficacy and Safety of Teriflunomide Versus Dimethyl Fumarate for the Treatment of Relapsing-Remitting Multiple Sclerosis, Neurology Research International (2021)
34. Cancer and Mortality Risks Among People With Multiple Sclerosis: A Population-Based Study in Isfahan, Iran, PLoS ONE (2024)
35. Cost of Illness of Multiple Sclerosis in Isfahan, Iran, From a Social Perspective: A Comparison of the Human-Capital and Friction-Cost Methods, Value in Health Regional Issues (2022)
36. Variability of the Response to Immunotherapy Among Subgroups of Patients With Multiple Sclerosis, European Journal of Neurology (2023)
37. Impact of Methodological Choices in Comparative Effectiveness Studies: Application in Natalizumab Versus Fingolimod Comparison Among Patients With Multiple Sclerosis, BMC Medical Research Methodology (2022)
38. Mycophenolate Mofetil in Combination With Interferon Beta-1A in the Treatment of Relapsing-Remitting Multiple Sclerosis: A Preliminary Study, Journal of Research in Medical Sciences (2011)
39. High Dose Vitamin D Intake and Quality of Life in Relapsing-Remitting Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Neurological Research (2016)
40. An Interdependence Between Gapvd1 Gene Polymorphism, Expression Level and Response to Interferon Beta in Patients With Multiple Sclerosis, Journal of Neuroimmunology (2021)
41. Mizaj Assessment in Multiple Sclerosis (Ms) Patients Based on Persian Medicine, Journal of Complementary and Integrative Medicine (2022)
42. Number and Volume of Demyelinative Plaques Can Predict the Response to Treatment in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2011)
43. Efficacy and Safety of Peginterferon Beta-1A Compared to Interferon Beta-1A in Relapsing Remitting Multiple Sclerosis Patients: A Phase 3, Randomized, Non-Inferiority Clinical Trial (Pegintegrity), Multiple Sclerosis and Related Disorders (2024)
44. Comparison of Betaferon, Avonex, and Rebif in Treatment of Relapsing-Remitting Multiple Sclerosis, Acta Neurologica Scandinavica (2006)
45. Rapid Exacerbation of Multiple Sclerosis Following the Initiation of Interferon-Β: Report of Nine Cases, Journal of Research in Medical Sciences (2011)
46. The Effects of Motivational Interviewing on Health Promoting Behaviors of Patients With Multiple Sclerosis, Iranian Journal of Nursing and Midwifery Research (2016)
47. Iranian Specialists’ Approach to Treatment Escalation in Multiple Sclerosis Patients With Cognitive Impairment, Current Journal of Neurology (2023)
48. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
49. The Relative Frequency of Using Complementary and Alternative Medicine in Patients With Multiple Sclerosis, Journal of Isfahan Medical School (2015)
50. Estimated Prevalence and Incidence of Multiple Sclerosis in Iran, European Neurology (2014)